ENDRA Life Sciences (NASDAQ:NDRA) Stock Price Down 5.1% – What’s Next?

Shares of ENDRA Life Sciences Inc. (NASDAQ:NDRA) were down 5.1% on Monday . The company traded as low as $3.70 and last traded at $3.75. Approximately 11,455 shares traded hands during trading, a decline of 46% from the average daily volume of 21,055 shares. The stock had previously closed at $3.95.

Analyst Upgrades and Downgrades

NDRA has been the topic of a number of analyst reports. Ascendiant Capital Markets cut their price target on ENDRA Life Sciences from $38.00 to $30.00 and set a “buy” rating on the stock in a report on Monday, December 8th. Wall Street Zen raised shares of ENDRA Life Sciences to a “sell” rating in a research report on Saturday, November 22nd. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of ENDRA Life Sciences in a report on Wednesday, January 21st. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $30.00.

ENDRA Life Sciences Stock Performance

The company has a 50 day moving average of $4.35 and a 200 day moving average of $4.98. The stock has a market capitalization of $2.81 million, a price-to-earnings ratio of -0.14 and a beta of 0.01.

Institutional Investors Weigh In On ENDRA Life Sciences

A hedge fund recently bought a new stake in ENDRA Life Sciences stock. Altium Capital Management LLC purchased a new position in shares of ENDRA Life Sciences Inc. (NASDAQ:NDRA) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 51,900 shares of the company’s stock, valued at approximately $235,000. ENDRA Life Sciences accounts for about 0.9% of Altium Capital Management LLC’s portfolio, making the stock its 17th largest holding. Altium Capital Management LLC owned 6.92% of ENDRA Life Sciences as of its most recent filing with the Securities and Exchange Commission. 1.19% of the stock is currently owned by hedge funds and other institutional investors.

About ENDRA Life Sciences

ENDRA Life Sciences, Inc (NASDAQ: NDRA) is a medical technology company headquartered in Ann Arbor, Michigan, that focuses on the development and commercialization of Thermoacoustic Enhanced Ultrasound (TAEUS™) imaging. The company’s proprietary TAEUS platform combines conventional ultrasound with thermoacoustic signals to provide non-invasive, real-time temperature monitoring of soft tissue. This technology is designed to improve the safety, efficacy and outcomes of thermal ablation procedures and other heat-based therapies.

ENDRA’s core product line centers on a compact, easy-to-integrate device that augments existing ultrasound systems.